Posted by Michael Wonder on 25 Aug 2022
AB Science announces that it has filed an application for conditional marketing authorisation to EMA for masitinib in the treatment of ALS
24 August 2022 - AB Science today announced that it has filed an application for conditional marketing authorisation to the EMA for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis.
This application has now been validated by EMA and review by the CHMP has begun.
